Our study introduced an on-line sequential injection chemiluminescence analysis approach based on luminol-potassium ferricyanide/silver nanoparticles system for crizotinib detection. All experimental conditions were optimized and the developed method displayed a linear relationship over the concentration range of 0.01 -500 g mL -1 , (r = 0.999), with quantification/detection limit ratio = 0.01/0.003 g mL -1 . The suggested method was utilized to detect the selected drug in bulk powder, capsules and human serum. The drug was tested in the presence of different interfering species and no significant difference in the results was observed. Statistical analysis was carried out to compare the obtained data with those from other published articles and excellent agreement was found. The method was validated to ensure its suitability and its precision was tested using inter-day and intra-day assay.
INTRODUCTION

Crizotinib (CRZ) is chemically known as 3-[(1R)-1-(2,6-dichloro-3fluorophenyl) ethoxy]-5-
(1-piperridin-4-ylpyrazol-4-yl) pyridine-2-amine as depicted in '' Figure 1 ''. It acts as an anaplastic lymphoma kinase inhibitor and recommended for the treatment of lung carcinoma. [1] It is mainly used in patients having large cell lung cancer. Recently, its binary medication with dasatinib may be evaluated to be used for the treatment of high grade glioma. [2] It is approved by Food and Drug Administration (FDA) in 2011 and manufactured by pfizer, Inc. under trade name Xalkori ® capsules.
Figure 1: Chemical structure of crizotinib
In literature survey few analytical methods have been reported for the determination of CRZ in bulk powder, dosage forms and biological fluids. These methods include, spectrofluorimetry, [3] spectrophotometry [4, 5] and liquid chromatography-tandem mass spectrometry. [6] [7] [8] The use of nanotechnology in analytical chemistry field facilitates the evaluation and detection of pharmaceutical drugs in very small levels, increase the suitability of the analytical methods and cut down the cost of analytical analysis.
Currently, silver nanoparticles are the most studied nanostructure in various branches of science. These nanoparticles have potential applications in drug delivery systems [9] biomedical [10, 11] and electrochemical analysis. [12] [13] [14] [15] Our study aimed to introduce a new sequential injection chemiluminescence analysis (SIA-CL) method for the determination of CRZ. The current method depends on the enhancement effect of silver nanoparticles (AgNPs) on luminol-ferricyanide system to produce a strong CL signal in alkaline medium. The CL intensity could be clearly enhanced in the presence of magnesium stearate and titanium dioxide were purchased from BDH chemical suppliers, (Poole, UK).
Apparatus
Different instruments were used in this study including, scanning electron microscope (SEM, Hitachi, Japan) for characterization of the prepared AgNPs. Transmission electron microscope (TEM) was also used to determine the particle size and the surface distribution of the prepared nanoparticles. Ultrospec-2100 pro spectrophotometer (Cambridge, UK) was used to detect the UV-spectrum of AgNPs. The chemiluminescence detection of CRZ was recorded using FIAlab-3500 instrument (Seattle, USA) a sequential injection analysis (SIA) system which connected with ALM-3200 autosampler and FIAlab software version 5.9.321 was used for data acquisition.
Samples preparation
Preparation of standard drug solution
To prepare a stock standard CRZ solution of concentration 1000 g mL -1 , approximately 0.1 mg of the CRZ pure powder was dissolved in 100 mL methanol. The required working solutions were obtained by serial dilution with the same solvent to prepare 0.01-500 g mL -1 of drug samples.
Preparation of pharmaceutical dosage form samples
The content of 10 capsules of Xalkori ® 250 mg/capsule was mixed well and accurate weight equivalent to 0.1 mg of CRZ was dissolved in methanol and ultrasonicated for 15 min. Then filtered using 0.22 μm membrane filter and serial dilution using methanol was carried out to prepare working solutions ranging from 0.01-500 g mL -1 . The mean % recoveries were obtained using calibration graph after utilizing the suggested CL method for the analysis of samples.
Preparation of serum samples
Aliquots of CRZ were used to spike approximately 1.0 ml of serum and transferred to centrifugation tubes. Then left aside for 5 min and the removal of the possible interferences was performed using 1.0 mL acetonitrile, 0.1 mL of 0.1 mol L -1 NaOH and 1.0 mL of (5.0%
w/v) ZnSO 4 .7H 2 O. [16] The clear supernatant layer which produced after centrifugation at 3500 rpm for 30 min was filtered and serial dilution sing methanol was carried out to prepare the CRZ concentration range of 0.01-500 g mL -1 .
Synthesis of silver nanoparticles AgNPs
The carried out per test solution and the average CL intensity was taken for the calibration. All measurements were computer controlled to ensure precise, timing of pump, valve movements and carried out at ambient temperature 25±1˚C.
Calibration
The experimental conditions for the determination of CRZ were optimized and the calibration graph was constructed. To plot the calibration graph, 8 experimental points for the investigated drug concentrations were taken vs. the CL intensity. The aspirated samples were triplicated to evaluate the mean peak heights. The linear regression was utilized for fitting the graph.
RESULTS AND DISCUSSION
Characterization of AgNPs using UV-spectrophotometry
UV-spectrophotometry was used to confirm the synthesized AgNPs. The prepared nanoparticles were examined using UV-Vis spectrum at λ 
Characterization of AgNPs using SEM and TEM
SEM was used to evaluate the surface morphology of the synthesized AgNPs. Figure 4a showed an image of the spherical AgNPs. Furthermore, TEM was applied to detect the particle size and the surface distribution of the prepared AgNPs. Approximately 20 nm was the particle size which detected as shown in Figure 4b . World Journal of Pharmacy and Pharmaceutical Sciences observed in Figure 5 , that poor CL signal was noticed by using potassium periodate and potassium permanganate. While, sharp CL signals were recorded by using potassium ferricyanide as well as hydrogen peroxide. Also, we can observe that luminol-potassium ferricyanide system gave a higher CL intensity rather than in the case of luminol-hydrogen peroxide system. Therefore, potassium ferricyanide was considered for further experimental studies. and CRZ sample 10 g mL -1
Effect of silver nanoparticles volume
The using of AgNPs can be greatly affecting the CL intensity of luminol-ferricyanide system. 
Detection of CRZ using SIA-CL system
AgNPs-luminol-ferricyanide CL system was applied to determine CRZ in its pure form. As shown in Figure 10 , we can noticed that the developed method displayed a linear relationship over a concentration range of 0.01-500 g mL -1 (r = 0.9993) with lower quantification limit/detection limit ratio of 0.01/0.003 g mL -1 . Method reproducibility was investigated and the % RSD was 1.2% indicating the suitability of the developed method for the detection of CRZ '' Table 2 ''. 
Effect of foreign substances
The selectivity of the developed method was tested by applying the method of analysis to the drug solution in the presence of certain common species such as minerals including (sodium, potassium, calcium and magnesium), some additive coformulated compounds such as (titanium dioxide, magnesium stearate and starch). Furthermore, the selectivity was also checked in the presence of some amino acids such as adrenaline, dopamine, cystine, histamine and tyrosine. The used test solution was 10 g mL -1 for CRZ as well as interfering substance. 
Method validation
Method validity was evaluated using ICH guidelines. [17] Various parameters were investigated including, linearity, lower detection and quantification limits, accuracy, precision and robustness. 
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Lower limit of detection (LOD)
The lower limit of detection was calculated using signal to noise ratio and the equation S/N=2 was used to calculate it. Lower detection limit was recorded and reported in Table 2 as 0.003 g mL -1 .
Quantification limit (LOQ)
The quantification limit of CRZ was evaluated by the suggested AgNPs-luminol-ferricyanide SIA-CL method, signal-to-noise ratio equal to 10 was performed for such evaluation and the calculated quantification limit was found to be 0.01 g mL -1 .
Accuracy
The standard addition method was employed to evaluate the accuracy of the proposed AgNPs-luminol-ferricyanide SIA-CL method. The obtained results were calculated in terms of mean percentage recoveries. The calculated % recovery was 99.15±1.1%.
Precision
The evaluation of the suggested AgNPs-luminol-ferricyanide CL method precision was carried out using the terms intra-day and inter-day assay. The studies were performed by repeating the determination of CRZ solution to nine replicates. The calculated % RSD values were 1.2% and 1.3% for intra-day and inter-day assay, respectively. The above % RSD value is less than 2% indicating high precision '' Table 4 ''. The robustness of the method was carried out by changing the flow rate, aspirate rate or volume of reagents and sample using 100±10 µL s -1 , 30±5 µL and 60±5 µL, respectively.
Close agreement between the obtained results and those recorded by standard CRZ solutions was found. 99.6±0.8% is the % recovery which was found from this study.
Analytical applications
Herein, we will mention the employing of the developed SIA-CL method for the detection of CRZ. Table 5 addressed the data obtained from the analysis of the selected drug in pure form using AgNPs-luminol-ferricyanide CL system. The statistical methods such as Student's t-test and F-test [18] were used and the results are compared with those obtained from the previously reported spectrophotometric method [4] which is based on the reaction of CRZ with a chromogenic reagent 1,2-naphthoquinone-4-sulphonate at maximum absorption peak at 490
nm. The results revealed high precision and accuracy. Furthermore, the SIA-CL method was applied for detecting the selected drug in its capsules, (Xalkori ® 250 mg/capsule). Table 6 summarized the obtained data which found to be 99.5±0.6. The suitability of the proposed method to detect CRZ was examined using human serum. Satisfactory results (98.9 ± 1.4)
were obtained as found in Table 7 . 
